Treatment outcomes
ADENOCARCINOMA, DISEASE
Up to December 31, 2020, the median follow‐up time for censored patients was 32.4 months (95% CI, 31.05–33.75). The median PFS was 6.50 months (95% CI, 2.89–10.11) and the median OS was 16.9 months (95% CI, 13.58–20.22) (Figure Survival analysis. (A) Progression‐free survival and (B) Overall survival analysis of all patients; (C and D) Subgroup analysis of sPCI, comparison of progression‐free survival and overall survival between sPCI ≤12 and. sPCI >12; *The area between the red dotted lines indicates the 95% confidence interval.** Short, vertical lines on the survival curve indicate censored data.Efficacy evaluation (Abbreviations: DCR, Disease Control Rate; ORR, Overall Response Rate.Further subgroup analysis of baseline characteristics and treatment for survival was conducted, and the results showed that pre‐treatment sPCI was a significant prognostic factor for PFS and OS (Table Subgroup analysis of survivalAbbreviations: Ade, Adenocarcinoma; SRCC, Signet‐ring cell carcinoma.